Cinacalcet Hcl
Brand names: Cinacalcet Hcl, Sensipar
At a glance
- Medicare prescriptions, 2024
- 196,479
- Medicare drug cost
- $54.9M
- Average cost per prescription
- $279
- Clinicians who prescribed it
- 7,242
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Sensipar is a positive modulator of the calcium sensing receptor indicated for: Secondary Hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis. Limitations of Use:
From the FDA-approved prescribing information (label dated December 2025). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Nephrology (Kidney) 44.9%
- Endocrinology & Diabetes 22.1%
- Internal Medicine 11.3%
- Nurse Practitioners 11.0%
- Family Medicine 4.7%
- Physician Assistants 2.6%
- Geriatric Medicine 1.1%
- Hospitalist 0.5%
- General Practice 0.4%
- Emergency Medicine 0.2%
- Cardiology 0.2%
- Urology 0.1%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 18% from 2019 to 2024.
Biggest change by state since 2019
- Ohio +35%
- Virginia +30%
- Georgia +30%
- Florida +27%
- Louisiana +27%
- New York (smallest change) +4%
- Tennessee (smallest change) +5%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 1 maker on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Amgen Inc
| Strength | Looks like | Imprint |
|---|---|---|
| 30 mg | green oval tablet, 10 mm | AMG 30 |
| 60 mg | green oval tablet, 12 mm | AMG 60 |
| 90 mg | green oval tablet, 14 mm | AMG 90 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
9 recalls since 2020
- Oct 2026 · Strides Pharma Inc · Class II
Failed dissolution specifications - Jun 2026 · Cipla USA, Inc. · Class II
cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI). - Jun 2026 · Amgen, Inc. · Class II
CGMP Deviations - Mar 2026 · Cipla USA, Inc. · Class II
CGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit - Nov 2025 · Cipla USA, Inc. · Class II
CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits. - Jul 2025 · Strides Pharma, Inc. · Class II
Failed Dissolution Specifications. - Oct 2024 · Accord Healthcare, Inc. · Class II
CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits. - Oct 2024 · Dr. Reddy's Laboratories, Inc. · Class II
CGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.